Recent examination that raise interrogate something like the benefits of the cholesterol medication Vytorin, manufactured by way of Merck and Schering-Plough, and the refuge of the integer 2 diabetes tending Avandia, manufactured by GlaxoSmithKline, be “reigniting debate” about the FDA agreement association surrounded by support of different medication, the Wall Street Journal reports. House Energy and Commerce Committee appendage John Dingell (D-Mich.) and Bart Stupak (D-Mich.) by the side of Thursday dispatch assignment to the American Heart Association, the American College of Cardiology, Merck and Schering-Plough to charge rumour about Vytorin, and Sen. Chuck Grassley (R-Iowa) on Thursday instigate a distinctive reconnaissance into the medication.

According to the Journal, the “lawmakers’ delight be the best modern signal that the dither over” Vytorin, in plonk of resourcefully as the safety concern about Avandia, “is group new fluid to a long-running debate” about the management of “surrogate markers” in the FDA approval process. FDA conceded Vytorin and Avandia in ample part underneath on tribute that they backing uniformity cholesterol and blood sugar gradation, respectively, subsequent to those measures “believed to echo defining clinical benefits” that “serve as proxy familiar sight, or surrogates, for the drug’s broader and more important effect on the article,” the Journal reports. The use of surrogate markers help decline approval times for new medications because “studies can collectively be shorter, smaller amount important and cheaper,” but the markers “can be to be regard with suspicion,” according to the Journal.

Grassley said that, “in wishy-washy of what’s happen with Avandia and Vytorin, conceivably the FDA wants to re-examine when it’s apposite to use surrogate endpoints.” He added, “These two cases also engineer more noticeable the hurry of vigilant postmarketing subsequent to and the musical sound for for more postmarketing studies to address important safety questions.” Stupak said that “people taking Vytorin are doing so because they sense it will reduce their stake of heart allusion.” In adjunct, he said, “It would make power for FDA to call for manufacturer to conduct an endpoint study to establish whether Vytorin only reduce cholesterol or if it also reduces heart attack.” FDA official said that they would fathom the use of surrogate markers in the agency approval process. A “shift by the FDA toward tougher scrutiny of new drugs could affix hundreds of millions of dollars to the price of evolving a pills at a instance when greater than a few capacious drug architect are struggling to sheep aloft resource pipelines,” the Journal reports (Wilde Mathews/Winslow, Wall Street Journal, 1/25).

Reprinted with humane agreement from You can do over the stuffed Kaiser Daily Health Policy Report, twirl upside down the archives, or sign up for email transference at /dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a uncommitted service of The Henry J. Kaiser Family Foundation 2005 Advisory Board Company and Kaiser Family Foundation. All rights kept support.

This entry was posted on Sunday, April 13th, 2008 at 9:58 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.